Introduction
============

Since Ralph Steinman first described a new subset of cells characterized by tree-like processes in 1973 ([@B109]), knowledge about dendritic cells (DC) in mice and humans has grown exponentially. These cells were originally identified as important players in the defense against "foreign" pathogens, but it turns out that they are similarly crucial in initiating immune responses against tumor-associated antigens ([@B115]). Immature DC engulf extracellular antigens, but in the absence of appropriate danger signals, they induce peripheral tolerance. Only after appropriate activation, DC release cytokines and chemokines, undergo a maturation process, and migrate toward secondary lymphatic tissues to induce cytotoxic responses by other immune cells ([@B86]; [@B78]).

In this perspective paper, we will focus on the role of CD8α-expressing DC. CD8 serves as useful subset marker for murine DC, which are highly efficient in cross-presenting foreign, self, and---most likely---tumor-associated antigens, although evidence is lacking that CD8 expression plays any role in the development and function of these cells ([@B106]). So far, CD8 expression on human DC has not been reported ([@B81]). However, we report here a serendipitous finding of CD8α expression on human plasmacytoid dendritic cells (PDC) after stimulation with herpes simplex virus type 1 (HSV-1), which characterizes a highly activated subset of PDC. We will discuss how the knowledge about CD8α-expressing murine DC may translate into functions of CD8α-expressing human PDC. For the background of this topic, the reader is referred to excellent review articles by respected colleagues ([@B117]; [@B106]; [@B57]; [@B83]; [@B10]; [@B14]).

Murine CD8α^+^ DC: Prominent Cross-presentation
===============================================

In the murine system, several different DC populations exist: lymphoid-organ resident CD8α^+^ or CD8α^--^ DC; migratory dermal CD103^+^ or CD103^--^ DC, which migrate to lymphatic tissue; Langerhans cells in the skin; inflammatory DC, which develop from monocytes; and PDC ([@B120]; [@B16]; [@B43], [@B44]; [@B67]; [@B89]; [@B57]). CD8α is a marker for lymphoid tissue-resident DC, which make up roughly 20% of spleen DC and 70% of thymic DC, whereas only 0.2% of peripheral blood mononuclear cells are CD8α^+^ DC ([@B23]; [@B119]; [@B30]; [@B47]; [@B106]). These cells express a CD8αα homodimer rather than the CD8αß heterodimer on T cells ([@B120], [@B119]). Precursors of CD8α^+^ DC may lack CD8 expression ([@B74]). Apart from the classical CD8α^+^ DC population, this molecule is expressed by murine PDC in the spleen ([@B84]) and other migratory DC after activation ([@B5], [@B6]; [@B77]; [@B47]). Mice with a knock-out for interferon regulatory factor (IRF) 8 neither develop CD8α^+^ DC nor PDC ([@B96]; [@B2]; [@B114]), whereas Batf3-deficient mice are only deficient in CD8α^+^ DC ([@B48]; [@B34]).

Amongst other receptors, the murine CD8α^+^ DC subset expresses CD11c, CD24, CD36, Necl2, MHC-II, the integrin CD103, the lectins CD205, CLEC9A, CLEC12A, and langerin (CD207) ([@B106]). CLEC9A and CD36 are both involved in recognizing late apoptotic or necrotic cells ([@B1]; [@B18]; [@B51]; [@B93]). Murine CD8α^+^ DC also express TLR3 and TLR9 ([@B35]), and respond to TLR stimulation with proinflammatory IL-12 secretion and at least some type I interferon production ([@B49]). Upon stimulation, CD8α^+^ DC upregulate costimulatory markers CD40, CD80, and CD86 as well as CD25, CD62L, and MHC-II ([@B123]).

CD8α^+^ DC are most efficient in antigen cross-presentation, a process in which extracellular antigen is not presented on MHC-II to CD4^+^ T cells, but instead shunted to MHC-I with subsequent induction of CD8^+^ T cells. Cross-presentation occurs through the cytosolic or vacuolar pathway ([@B57]). The former involves proteasomal degradation with subsequent transport of peptides into the endoplasmic reticulum via transporter associated with antigen processing 1 (TAP), whereas the latter is based on lysosomal proteolysis with subsequent loading of peptides onto MHC-I molecules ([@B57]).

In this respect, CD8α^+^ DC, but not CD8α^--^ DC, were shown to cross-prime using a TAP-dependent pathway ([@B26]; [@B87]; [@B97]; [@B68]). CD8α^+^ DC have been reported to selectively engulf dying cells *in vitro* and *in vivo* and present on MHC-I via a proteasome-dependent pathway ([@B53]; [@B100]). In these cells, endosomal acidification is limited ([@B95]), which fosters limited antigen degradation and efficient transport of the antigen to the cytosol ([@B25]). Overexpression of MHC-I loading complexes ([@B32]) by CD8α^+^ DC and expression of chemokine receptor XCR1, whose ligand XCL1 is secreted by activated CD8^+^ T cells, contribute to antigen cross-presentation and differentiation of cytotoxic T cells ([@B31]).

In HSV infections, CD8α^+^ DC are able to present viral antigens and prime naïve CD4^+^ and CD8^+^ T cells, which appears to be mediated by cross-presentation ([@B3]; [@B108]; [@B12],[@B13]; [@B122]; [@B11]; [@B66]). It is still a matter of debate how the viral antigen is transported from peripheral infected tissue to the lymphoid-resident CD8α^+^ DC. In this process, mainly other (migratory) DC are reported to be involved ([@B125]; [@B19]; [@B4]; [@B11]; [@B56]). These migratory DC either capture viral antigens or are infected within the peripheral tissue, although reduced migratory capacity has been reported for HSV-infected DC ([@B58]; [@B36]; [@B90]). The transfer of viral antigen can occur via exosomes, gap junctions, or uptake of apoptotic material following death of migratory DC ([@B113]; [@B75]). Another option is "crossdressing", i.e., the transfer of preformed MHC-I complexes loaded with peptides from infected cells to murine DC via secreted membrane vesicles or transfer of membrane fragments (trogocytosis) ([@B113]; [@B121]; [@B57]).

Murine CD8α^+^ PDC: Cross-presentation Help
===========================================

Murine PDC were identified in the spleen of mice ([@B7]; [@B85]). Amongst other surface receptors, they express Ly6C, B220, and CD11c. Upon stimulation, type I interferons---and to a minor extent IL-12---are induced, and costimulatory markers CD40, CD69, CD80, and CD86 are upregulated ([@B7]; [@B84]; [@B72]). Unstimulated murine PDC express CD8α only to a minor extent, while exposure to CpG or viruses enhances expression of this molecule ([@B82]; [@B84], [@B85]). When CD8α^+^ and CD8α^--^ PDC were separated and subsequently stimulated, they did not differ in cytokine production ([@B84]).

A few publications report TAP-dependent cross-presentation of soluble and particulate antigen by murine PDC after TLR ligation ([@B105]; [@B80]; [@B63]). The majority of authors, however, deny cross-presentation by murine PDC ([@B22]; [@B55]; [@B94]; [@B42]; [@B91]; [@B46]). *In vitro* stimulation of murine PDC with HSV-1 or influenza allowed priming of CD8^+^ T cells ([@B12]). In *in vivo* HSV-1 infections, however, PDC do not participate in active cross-presentation ([@B3]; [@B66]; [@B110]). Still, murine PDC appear to be important in enhancing cross-presentation by other DC. An explanation of this phenomenon could be that type I interferons increase cross-presentation by decreasing antigen degradation in endocytic compartments and stimulating the survival of CD8α^+^ DC ([@B28]; [@B40]; [@B70]). In this respect, depletion of murine PDC was reported to impair CTL-mediated HSV-1 eradication in a CD2-, CD40L-, and type I interferon-dependent manner ([@B124]). Also in the lymphocytic choriomeningitis model, virus-induced type I interferons were required for cross-priming of CD8^+^ T cells ([@B65]). When PDC were depleted in CLEC4C-DTR mice, PDC proved to be important for inducing CD8^+^ T cell responses in systemic HSV-1 and HSV-2 infections ([@B110]). Further functions of PDC in murine HSV-1 and HSV-2 infections are reviewed in ([@B101]).

Human Orthologue of CD8α^+^ DC: Cross-presentation Following Activation
=======================================================================

The conventional human blood DC population consist of three subsets specifically expressing CD1c (BDCA1), CD16, or CD141 (BDCA3) ([@B33]; [@B73]). Evidence is accumulating that the CD11c^+^ CD141^+^ DC subset represents the human orthologue of murine CD8α^+^ DC. These cells can be detected in lymphatic tissues such as lymph nodes, tonsils, bone marrow, spleen, and also liver ([@B41]; [@B69]; [@B116]; [@B9]; [@B89]). Genome-wide expression analyses revealed a similar transcriptomal signature between CD141^+^ human DC and murine CD8α^+^ DC ([@B92]). Both subsets express Necl2 ([@B41]), CLEC9A ([@B18]; [@B51]; [@B93]; [@B59]; [@B99]), TLR3 ([@B35]; [@B69]; [@B59]), as well as CD207, Batf3, and IRF8 ([@B89]). BDCA3^+^ DC also express the chemokine receptor XCR1 and respond to respective ligands ([@B8]; [@B24]). Similar to murine CD8α^+^ DC, human BDCA3^+^ DC respond to TLR3 ligation with production of lambda interferons ([@B64]). In contrast to murine CD8α^+^ DC, human BDCA3^+^ DC do not express TLR9 ([@B59]).

Lymphoid tissue-derived human BDCA3^+^ DC were shown to be at least equivalent to other human DC subsets in cross-presenting soluble or cell-associated antigens, even in the absence of activation ([@B104], [@B103]). This process can be enhanced by stimulation with TLR3 ligands, inducing superior cross-presenting activity by blood-derived BDCA3^+^ DC with induction of CD8^+^ T cell responses ([@B88]; [@B8]; [@B24]; [@B59]). There is evidence that cross-presentation by myeloid DC plays a role in human herpes virus infections ([@B15]), but the importance of BDCA3^+^ DC needs to be further clarified.

Human CD8α^+^ PDC: Cross-presentation Help Following Viral Activation?
======================================================================

In 1999, two independent groups identified human PDC as major producers of type I interferons in the blood ([@B21]; [@B107]). Amongst other receptors, PDC express BDCA2 and BDCA4, MHC-II, the lymph node-homing receptors CD62L and CCR7 (CD197), and costimulatory molecules (CD40, CD80, CD86, CD270, CD274, CD275) ([@B20]; [@B33]; [@B52]; [@B54]; [@B29]; [@B102], [@B101]; [@B17]). PDC recognize single-stranded RNA and CpG molecules via TLR7 and TLR9, respectively ([@B61]).

Whether human PDC can cross-present soluble or particulate antigens is still a matter of debate. Viral antigen derived from influenza, recombinant vaccinia, tick-borne encephalitis or human immunodeficiency type I virus infection was taken up into recycling endosomes, loaded onto MHC-I molecules, and presented to CD8^+^ T cells ([@B38],[@B39]; [@B50]; [@B27]; [@B71]; [@B79]; [@B112]). In addition, antigen loaded on synthetic microparticles or soluble tumor-associated antigen was presented to CD8^+^ T cells by exposed PDC ([@B111]; [@B45]; [@B103]). In contrast, other groups report no or only minor cross-presenting capacities of human PDC ([@B98]; [@B8]; [@B24]).

An early report by Fitzgerald-Bocarsly described the "interferon-producing cells" as being important for the lysis of HSV-infected fibroblasts ([@B37]). PDC infiltrate herpetic lesions in the genital tract and tightly colocalize with NK and T cells ([@B29]). HSV-stimulated human PDC induce migration of activated T and NK cells via chemokine secretion ([@B76]), and contribute to the activation of NK cells via IFNα- and TNFα-dependent mechanism ([@B118]). In addition, HSV-exposed PDC were shown to prime IL-10 and IFN-γ production by cytotoxic regulatory CD4^+^ T cells ([@B60]; [@B62]).

So far, expression of CD8 on human PDC has not been reported. Since the expression of this molecule on the surface of human PDC may define new and yet unknown capacities of these cells, we investigated whether PDC might upregulate these molecules upon viral stimulation. Recently, we analyzed the expression profile of human PDC, which were purified from PBMC of six donors. After exposure to IL-3 or IL-3 plus UV-inactivated HSV-1 (HSV~UV~), RNA was extracted from these cells and hybridized to a Human Genome U133 Plus 2_0 Array (Affymetrix, Santa Clara, CA, USA) ([@B102]). In these analyses, we focused on the expression and regulation of surface receptors on PDC. Notably, the signal for CD8α expression increased from 57.2 to 100.1, which was slightly above the arbitrary threshold of 95, reflecting the expression signal of TLR9. In contrast, three probe sets for CD8β remained below this threshold. These data suggested a potential expression of CD8α on PDC upon stimulation with HSV~UV~.

To corroborate these data, we isolated PDC from a total of 15 different donors, and investigated CD8α expression on these cells in independent experiments after exposure to IL-3 (*n* = 16), IL-3 plus HSV~UV~ (*n* = 16), or IL-3 plus infectious HSV-1 (HSV~INF~, *n* = 6) for 40 h. Flow cytometry confirmed a distinct expression of CD8α on a subset of HSV~UV~- and HSV~INF~-exposed PDC (Figure [1A](#F1){ref-type="fig"}). After stimulation with HSV~UV~ or HSV~INF~, the percentage of CD8α-expressing PDC was significantly higher compared to PDC within freshly isolated PBMC (*n* = 9) (*p* \< 0.001 for HSV~UV~ and *p* \< 0.05 for HSV~INF~, unpaired *t*-test) and purified PDC that were cultivated in the presence of IL-3 only (*p* \< 0.001 for HSV~UV~ and *p* \< 0.05 for HSV~INF~, paired *t*-test) (Figure [1A](#F1){ref-type="fig"}). CD8α expression was not different between HSV~UV~- and HSV~INF~-exposed PDC (*p* = 0.27, n.s.). When we stained in parallel for CD8α and CD8β expression, we confirmed expression of CD8α by flow cytometry, while CD8β was neither detected on PDC exposed to HSV~UV~ (*n* = 4) nor HSV~INF~ (*n* = 3) (Figure [1B](#F1){ref-type="fig"}). These data indicated that PDC did not express a heterodimeric CD8αβ receptor upon stimulation. In further analyses, we investigated the kinetics of CD8α expression (*n* = 4). After exposure to HSV~UV~, the percentage of CD8α-expressing cells increased by day 1, but reached significance by day 2 post stimulation, compared to PDC cultivated with IL-3 alone (*n* \< 0.05, paired *t*-test). Expression of CD8β was not detected at any of the time points analyzed (*n* = 3) (Figure [1C](#F1){ref-type="fig"}).

![**Characterization of CD8α-expressing human plasmacytoid dendritic cells (PDC). (A)** Expression of CD8α on human PDC, as evaluated by flow cytometry within PBMC immediately after cell isolation (0 h) (*n* = 9) and after cultivation of purified PDC in the presence of IL-3 (10 ng/ml), IL-3 plus UV-inactivated herpes simplex virus type 1 (HSV~UV~) (*n* = 16) or infectious HSV-1 (HSV~INF~) (*n* = 6) (1 × 10^6^ plaque-forming units/ml) for 40 h. One representative example of PDC exposed to IL-3 (upper left panel) and IL-3 plus HSV~UV~ (lower left panel) and data of all donors including mean values (bars) are shown (right panel). **(B)** Representative expression of CD8α, not CD8β, on human PDC after exposure to IL-3 plus HSV~UV~ (upper panel, *n* = 4) or HSV~INF~ (lower panel, *n* = 3) for 40 h. **(C)** Kinetics of CD8α (*n* = 4) and CD8β (*n* = 3) expression after exposure of human PDC to IL-3 or IL-3 plus HSV~UV~ for 4 days. Data are presented as mean and standard deviation. **(D)** Expression of markers for costimulation (CD40, CD274), activation (CD69), maturation (CD83), and migration (CD197) on CD8α^+^ and CD8α^--^ human PDC after exposure to IL-3 plus HSV~UV~ for 40 h. The dotted lines represent isotype controls. For statistical analysis, MFI values were transformed logarithmically to obtain normal distribution. Expression of CD4 as well as CD2, CD46, CD80, and CD123 (data not shown) was not significantly different between the two PDC subsets. Mean and standard deviation of four different donors (except for CD274, *n* = 3). **(E)** After stimulation of human PDC with IL-3 plus HSV~UV~ for 40 h, cells were harvested and then separated using a CD8 cell isolation kit (Miltenyi Biotec, Bergisch-Gladbach, Germany). After stimulation with IL-3 or IL-3 plus HSV~UV~ for another 20 h, different cytokines were analyzed in the cell culture supernatants using a multiplex cytokine and chemokine panel on a luminex platform (Invitrogen/Life Technologies, Darmstadt, Germany, and Affymetrix/ebioscience, Frankfurt, Germany). Mean and standard deviation of three different donors. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001.](fmicb-06-00557-g0001){#F1}

To find out in how far CD8α^+^ and CD8α^--^ PDC differed from each other, we analyzed the expression of cell surface markers for costimulation (CD40, CD274), activation (CD69), maturation (CD83), and migration (CD197) on these two subsets. All these markers were significantly upregulated on CD8α^+^ PDC compared to CD8α^--^ PDC (*p* \< 0.05, paired *t*-test) (Figure [1D](#F1){ref-type="fig"}), while five other surface molecules (CD2, CD4, CD46, CD80, and CD123) were not differently regulated after HSV~UV~ stimulation. These data suggested that the subset of CD8α^+^ PDC was particularly activated. Eventually, we exposed PDC of three donors to HSV~UV~ for 40 h, separated these cells using a CD8 cell isolation kit, and exposed the CD8α^+^ and CD8α^--^ PDC to HSV~UV~ for another 20 h. Subsequently, cell culture supernatants were analyzed using a multiplex cytokine bead assay. Of a total of 25 cytokines, we found IFN-α, IL-8, IL-1RA, MIP-1α, MIP-1β, and MCP-1 upregulated in CD8α-expressing PDC. In contrast, IL-6 secretion was not different between the two subsets, and other cytokines were either not induced (IL-1β, IL-17, IFN-γ, GM-CSF, MIG, RANTES) or expressed only at very low levels (IL-2, IL-4, IL-5, IL-7, IL-12p40, IL-13, IL-15, eotaxin) (Figure [1E](#F1){ref-type="fig"}). IFN-α and IL-6 enhance T cell, B cell, and NK cell development and function; IL-8 recruits T cells and induces their degranulation; IL-1RA inhibits IL-1 induced T cell activation, and the chemokines MIP-1α, MIP-1β, and MCP-1 recruit immature DC, monocytes, and Th1 cells. Altogether, these data indicate that a subset of PDC gradually upregulates a homodimeric CD8α receptor upon HSV-1 stimulation, exposes a highly activated phenotype, and appears to be particularly active in recruiting other immune cells to the site of inflammation.

Conclusion
==========

This is---at least to our knowledge---the first report that a subset of human PDC is capable of expressing CD8α at the cell surface upon HSV-1 stimulation. This subset is phenotypically different from the CD8α^--^ PDC in expressing increased levels of markers for activation, costimulation, and migration. In parallel, CD8α^+^ PDC secrete enhanced levels of proinflammatory cytokines and chemokines. Therefore, this subset may play an important role in innate and adaptive immune defenses in HSV-1 infections. So far, it is unclear whether CD8α^+^ PDC are just a more activated subset, which "does better" than CD8α^--^ PDC, or whether they have additional or different functions, such as being actively involved in cross-presentation. Further studies are required to define the conditions under which PDC present antigen efficiently and which formulation of antigen fits best for PDC cross-presentation ([@B117]). Notably, murine knockouts for IRF8 lead to deficiencies in PDC and lymphoid-resident CD8α^+^ DC ([@B96]; [@B2]; [@B114]). This phenomenon may point to a common link in development and possibly function of these two cell populations. Further analyses of human CD8α-expressing PDC will delineate their role in the defense against viral infections, and---if viral vectors are used---also in anti-tumor responses.

Author Contributions
====================

PS, ST, and MW performed the experiments, JV contributed multiplex cytokine bead array data and performed proof-reading, and BS and PS wrote the manuscript.

Conflict of Interest Statement
------------------------------

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

We thank Bernhard Fleckenstein, Erlangen, and André Gessner, Regensburg, for continuous support, and Ulrike Samulowitz, Pfizer Oligonucleotide Therapeutics Unit, Coley Pharmaceutical GmbH, Düsseldorf, Germany, for performing cytokine bead arrays. Part of this work was supported by the doctoral training programs GK1071 ("Viruses of the immune system"; to PS) and GRK1660 ("Key signals of adaptive immune response"; to ST), and the "Akademie der Wissenschaften und Literatur zu Mainz."

DC

:   dendritic cells

HSV

:   Herpes simplex virus

IFN

:   interferon

IL

:   interleukin

PBMC

:   peripheral blood mononuclear cells

PDC

:   plasmacytoid dendritic cells.

[^1]: Edited by: *Laura Hertel, Children's Hospital Oakland Research Institute, USA*

[^2]: Reviewed by: *Giada Frascaroli, Ulm University Medical Center, Germany; Christiane S. Heilingloh, Universitätsklinikum Erlangen, Germany*

[^3]: This article was submitted to Virology, a section of the journal Frontiers in Microbiology.
